Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition

Sarah Caldwell
Data & Analytics

Brenda Snow
Authentic Patient Voice

Don Feiler
Brand Engagement

Ira Haimowitz
Closed-Loop Marketing

Adrienne Stevens, EdD
HCP Insights

Julia Laurin
Medication Adherence

Erin DeRuggiero
Non-Personal Promotion

Bud Bilanich
Success Coach